PRKAA1 and glioblastoma: Specifically, the TS-GBM cells were pre-treated with compound C and SBI-0206965 to inactivate AMPK/ULK1 pathway, and were subsequently treated with PD-L1-ex and stimulated with high-dose TMZ for 48 h, respectively.